References
- Aban, I. B., Cutter, G. R., and Mavinga, N. (2009), “Inferences and Power Analysis Concerning Two Negative Binomial Distributions With an Application to MRI Lesion Counts Data,” Computational Statistics & Data Analysis, 53, 820–833. DOI: https://doi.org/10.1016/j.csda.2008.07.034.
- Bateman, E. D., Reddel, H. K., O’Byrne, P. M., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Siwek-Posluszna, A., and FitzGerald, J. M. (2018), “As-Needed Budesonide-Formoterol Versus Maintenance Budesonide in Mild Asthma,” New England Journal of Medicine, 378, 1877–1887. DOI: https://doi.org/10.1056/NEJMoa1715275.
- Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C., and Vestbo, J. (2007), “Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease,” New England Journal of Medicine, 356, 775–789. DOI: https://doi.org/10.1056/NEJMoa063070.
- Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W. W., Ford, L., Sher, L., FitzGerald, J. M., Katelaris, C., Tohda, Y., Zhang, B., Staudinger, H., Pirozzi, G., Amin, N., Ruddy, M., Akinlade, B., Khan, A., Chao, J., Martincova, R., Graham, N. M. H., Hamilton, J. D., Swanson, B. N., Stahl, N., Yancopoulos, G. D., and Teper, A. (2018), “Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma,” New England Journal of Medicine, 378, 2486–2496. DOI: https://doi.org/10.1056/NEJMoa1804092.
- Chowdhury, S., Tiwari, R. C., and Ghosh, S. (2019), “Non-Inferiority Testing for Risk Ratio, Odds Ratio and Number Needed to Treat in Three-Arm Trial,” Computational Statistics & Data Analysis, 132, 70–83. DOI: https://doi.org/10.1016/j.csda.2018.08.018.
- Committee for Medicinal Products for Human Use (2005), “Guideline on the Choice of the Non-Inferiority Margin,” available at https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-choice-non-inferiority-margin_en.pdf.
- Committee for Medicinal Products for Human Use (2012), “Guideline on Clinical Investigation of Medicinal Products in the Treatment of Chronic Obstructive Pulmonary Disease (COPD),” available at https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-chronic-obstructive-pulmonary-disease_en.pdf.
- Committee for Medicinal Products for Human Use (2015), “Guideline on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis,” available at https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis_en-0.pdf.
- Committee for Medicinal Products for Human Use (2016), “Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Asthma,” available at https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-asthma_en.pdf.
- Cook, R. J., Lee, K.-A., and Li, H. (2007), “Non-Inferiority Trial Design for Recurrent Events,” Statistics in Medicine, 26, 4563–4577. DOI: https://doi.org/10.1002/sim.2885.
- Corren, J., Parnes, J. R., Wang, L., Mo, M., Roseti, S. L., Griffiths, J. M., and van der Merwe, R. (2017), “Tezepelumab in Adults With Uncontrolled Asthma,” New England Journal of Medicine, 377, 936–946. DOI: https://doi.org/10.1056/NEJMoa1704064.
- Fagerland, M. W., and Sandvik, L. (2009), “The Wilcoxon-Mann-Whitney Test Under Scrutiny,” Statistics in Medicine, 28, 1487–1497. DOI: https://doi.org/10.1002/sim.3561.
- Food and Drug Administration (2016), “Non-Inferiority Clinical Trials to Establish Effectiveness,” available at https://www.fda.gov/media/78504/download.
- Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., Viglietta, V., and Dawson, K. T. (2012), “Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis,” New England Journal of Medicine, 367, 1087–1097. DOI: https://doi.org/10.1056/NEJMoa1206328.
- Friede, T., Häring, D. A., and Schmidli, H. (2019), “Blinded Continuous Monitoring in Clinical Trials With Recurrent Event Endpoints,” Pharmaceutical Statistics, 18, 54–64. DOI: https://doi.org/10.1002/pst.1907.
- Friede, T., and Schmidli, H. (2010), “Blinded Sample Size Reestimation With Negative Binomial Counts in Superiority and Non-Inferiority Trials,” Methods of Information in Medicine, 49, 618–624. DOI: https://doi.org/10.3414/ME09-02-0060.
- Hauschke, D., and Pigeot, I. (2005), “Establishing Efficacy of a New Experimental Treatment in the ‘Gold Standard’ Design,” Biometrical Journal, 47, 782–786. DOI: https://doi.org/10.1002/bimj.200510169.
- Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H. P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., Traboulsee, A., Wolinsky, J. S., Arnold, D. L., Klingelschmitt, G., Masterman, D., Fontoura, P., Belachew, S., Chin, P., Mairon, N., Garren, H., and Kappos, L. (2017), “Ocrelizumab Versus Interferon Beta-1a in Relapsing Multiple Sclerosis,” New England Journal of Medicine, 376, 221–234. DOI: https://doi.org/10.1056/NEJMoa1601277.
- Hida, E., and Tango, T. (2011a), “On the Three-Arm Non-Inferiority Trial Including a Placebo With a Prespecified Margin,” Statistics in Medicine, 30, 224–231. DOI: https://doi.org/10.1002/sim.4099.
- Hida, E., and Tango, T. (2011b), “Response to Joachim Röhmel and Iris Pigeot,” Statistics in Medicine, 30, 3165–3165.
- Hida, E., and Tango, T. (2013), “Three-Arm Noninferiority Trials With a Prespecified Margin for Inference of the Difference in the Proportions of Binary Endpoints,” Journal of Biopharmaceutical Statistics, 23, 774–789.
- Hida, E., and Tango, T. (2018), “Design and Analysis of a 3-Arm Noninferiority Trial With a Prespecified Margin for the Hazard Ratio,” Pharmaceutical Statistics, 17, 489–503.
- Holzhauer, B., Wang, C., and Schmidli, H. (2018), “Evidence Synthesis From Aggregate Recurrent Event Data for Clinical Trial Design and Analysis,” Statistics in Medicine, 37, 867–882. DOI: https://doi.org/10.1002/sim.7549.
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2000), “Choice of Control Group and Related Issues in Clinical Trials,” available at https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf.
- Kappos, L., Radue, E. W., O’Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., and Burtin, P. (2010), “A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis,” New England Journal of Medicine, 362, 387–401. DOI: https://doi.org/10.1056/NEJMoa0909494.
- Keene, O. N., Calverley, P. M. A., Jones, P. W., Vestbo, J., and Anderson, J. A. (2008), “Statistical Analysis of Exacerbation Rates in COPD: Tristan and Isolde Revisited,” European Respiratory Journal, 32, 17–24. DOI: https://doi.org/10.1183/09031936.00161507.
- Keene, O. N., Jones, M. R. K., Lane, P. W., and Anderson, J. (2007), “Analysis of Exacerbation Rates in Asthma and Chronic Obstructive Pulmonary Disease: Example From the Tristan Study,” Pharmaceutical Statistics, 6, 89–97. DOI: https://doi.org/10.1002/pst.250.
- Keller, M. B., Ryan, N. D., Strober, M., Klein, R. G., Kutcher, S. P., Birmaher, B., Hagino, O. R., Koplewicz, H., Carlson, G. A., Clarke, G. N., Emslie, G. J., Feinberg, D., Geller, B., Kusumakar, V., Papatheodorou, G., Sack, W. H., Sweeney, M., Wagner, K. D., Weller, E. B., Winters, N. C., Oakes, R., and Mccafferty, J. P. (2001), “Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial,” Journal of the American Academy of Child & Adolescent Psychiatry, 40, 762–772. DOI: https://doi.org/10.1097/00004583-200107000-00010.
- Kieser, M., and Friede, T. (2007), “Planning and Analysis of Three-Arm Non-Inferiority Trials With Binary Endpoints,” Statistics in Medicine, 26, 253–273. DOI: https://doi.org/10.1002/sim.2543.
- Koch, A., and Röhmel, J. (2004), “Hypothesis Testing in the ‘Gold Standard’ Design for Proving the Efficacy of an Experimental Treatment Relative to Placebo and a Reference,” Journal of Biopharmaceutical Statistics, 14, 315–325. DOI: https://doi.org/10.1081/BIP-120037182.
- Kombrink, K., Munk, A., and Friede, T. (2013), “Design and Semiparametric Analysis of Non-Inferiority Trials With Active and Placebo Control for Censored Time-to-Event Data,” Statistics in Medicine, 32, 3055–3066. DOI: https://doi.org/10.1002/sim.5769.
- Kwong, K. S., Cheung, S. H., and Wen, M. J. (2010), “Sample Size Determination in Step-Up Testing Procedures for Multiple Comparisons With a Control,” Statistics in Medicine, 29, 2743–2756. DOI: https://doi.org/10.1002/sim.4045.
- Lawless, J. F. (1987), “Negative Binomial and Mixed Poisson Regression,” Canadian Journal of Statistics, 15, 209–225. DOI: https://doi.org/10.2307/3314912.
- Li, G., and Gao, S. (2010), “A Group Sequential Type Design for Three-Arm Non-Inferiority Trials With Binary Endpoints,” Biometrical Journal, 52, 504–518. DOI: https://doi.org/10.1002/bimj.200900188.
- Mann, H. B., and Whitney, D. R. (1947), “On a Test of Whether One of Two Random Variables Is Stochastically Larger Than the Other,” The Annals of Mathematical Statistics, 18, 50–60. DOI: https://doi.org/10.1214/aoms/1177730491.
- Massacesi, L., Tramacere, I., Amoroso, S., Battaglia, M. A., Benedetti, M. D., Filippini, G., La Mantia, L., Repice, A., Solari, A., Tedeschi, G., and Milanese, C. (2014), “Azathioprine Versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial,” PLoS One, 9, 1–13. DOI: https://doi.org/10.1371/journal.pone.0113371.
- McCullagh, P., and Nelder, J. A. (1989), Generalized Linear Models, New York: Chapman and Hall/CRC.
- Mielke, M., Munk, A., and Schacht, A. (2008), “The Assessment of Non-Inferiority in a Gold Standard Design With Censored, Exponentially Distributed Endpoints,” Statistics in Medicine, 27, 5093–5110. DOI: https://doi.org/10.1002/sim.3348.
- Montalban, X., Arnold, D. L., Weber, M. S., Staikov, I., Piasecka-Stryczynska, K., Willmer, J., Martin, E. C., Dangond, F., Syed, S., and Wolinsky, J. S. (2019), “Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis,” New England Journal of Medicine, 380, 2406–2417. DOI: https://doi.org/10.1056/NEJMoa1901981.
- Mütze, T., and Friede, T. (2017), “Blinded Sample Size Re-Estimation in Three-Arm Trials With ‘Gold Standard’ Design,” Statistics in Medicine, 36, 3636–3653. DOI: https://doi.org/10.1002/sim.7356.
- Mütze, T., Munk, A., and Friede, T. (2016), “Design and Analysis of Three-Arm Trials With Negative Binomially Distributed Endpoints,” Statistics in Medicine, 35, 505–521. DOI: https://doi.org/10.1002/sim.6738.
- Nierenberg, A. A., Greist, J. H., Mallinckrodt, C. H., Prakash, A., Sambunaris, A., Tollefson, G. D., and Wohlreich, M. M. (2007), “Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depressive Disorder: Onset of Antidepressant Action, a Non-Inferiority Study,” Current Medical Research and Opinion, 23, 401–416. DOI: https://doi.org/10.1185/030079906X167453.
- O’Byrne, P. M., FitzGerald, J. M., Bateman, E. D., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Ivanov, S., and Reddel, H. K. (2018), “Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma,” New England Journal of Medicine, 378, 1865–1876. DOI: https://doi.org/10.1056/NEJMoa1715274.
- Pavord, I. D., Chanez, P., Criner, G. J., Kerstjens, H. A. M., Korn, S., Lugogo, N., Martinot, J. B., Sagara, H., Albers, F. C., Bradford, E. S., Harris, S. S., Mayer, B., Rubin, D. B., Yancey, S. W., and Sciurba, F. C. (2017), “Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease,” New England Journal of Medicine, 377, 1613–1629. DOI: https://doi.org/10.1056/NEJMoa1708208.
- Pigeot, I., Schäfer, J., Röhmel, J., and Hauschke, D. (2003), “Assessing Non-Inferiority of a New Treatment in a Three-Arm Clinical Trial Including a Placebo,” Statistics in Medicine, 22, 883–899. DOI: https://doi.org/10.1002/sim.1450.
- R Core Team (2019), R: A Language and Environment for Statistical Computing, Vienna, Austria: R Foundation for Statistical Computing.
- Röhmel, J., and Pigeot, I. (2011), “Statistical Strategies for the Analysis of Clinical Trials With an Experimental Treatment, an Active Control and Placebo, and a Prespecified Fixed Non-Inferiority Margin for the Difference in Means,” Statistics in Medicine, 30, 3162–3164. DOI: https://doi.org/10.1002/sim.4299.
- Schlömer, P., and Brannath, W. (2013), “Group Sequential Designs for Three-Arm ‘Gold Standard’ Non-Inferiority Trials With Fixed Margin,” Statistics in Medicine, 32, 4875–4889. DOI: https://doi.org/10.1002/sim.5950.
- Stucke, K., and Kieser, M. (2012), “A General Approach for Sample Size Calculation for the Three-Arm ‘Gold Standard’ Non-Inferiority Design,” Statistics in Medicine, 31, 3579–3596. DOI: https://doi.org/10.1002/sim.5461.
- Tang, Y. (2015), “Sample Size Estimation for Negative Binomial Regression Comparing Rates of Recurrent Events With Unequal Follow-Up Time,” Journal of Biopharmaceutical Statistics, 25, 1100–1113. DOI: https://doi.org/10.1080/10543406.2014.971167.
- Tang, Y. (2018), “Sample Size for Comparing Negative Binomial Rates in Noninferiority and Equivalence Trials With Unequal Follow-Up Times,” Journal of Biopharmaceutical Statistics, 28, 475–491.
- Venables, W. N., and Ripley, B. D. (2002), Modern Applied Statistics With S, New York: Springer.
- Wang, L., and Fan, C. (2019), “Sample Size Calculations for Comparing Two Groups of Count Data,” Journal of Biopharmaceutical Statistics, 29, 115–127. DOI: https://doi.org/10.1080/10543406.2018.1489409.
- Wang, Y. C., Meyerson, L., Tang, Y. Q., and Qian, N. (2009), “Statistical Methods for the Analysis of Relapse Data in MS Clinical Trials,” Journal of the Neurological Sciences, 285, 206–211. DOI: https://doi.org/10.1016/j.jns.2009.07.017.
- Wedzicha, J. A., Banerji, D., Chapman, K. R., Vestbo, J., Roche, N., Ayers, R. T., Thach, C., Fogel, R., Patalano, F., and Vogelmeier, C. F. (2016), “Indacaterol-Glycopyrronium Versus Salmeterol-Fluticasone for COPD,” New England Journal of Medicine, 374, 2222–2234. DOI: https://doi.org/10.1056/NEJMoa1516385.
- Wilcoxon, F. (1945), “Individual Comparisons by Ranking Methods,” Biometrics Bulletin, 1, 80–83. DOI: https://doi.org/10.2307/3001968.
- Wise, R. A., Anzueto, A., Cotton, D., Dahl, R., Devins, T., Disse, B., Dusser, D., Joseph, E., Kattenbeck, S., Koenen-Bergmann, M., Pledger, G., and Calverley, P. (2013), “Tiotropium Respimat Inhaler and the Risk of Death in COPD,” New England Journal of Medicine, 369, 1491–1501. DOI: https://doi.org/10.1056/NEJMoa1303342.
- Wu, Y., Li, Y., Hou, Y., Li, K., and Zhou, X. (2018), “Study Duration for Three-Arm Non-Inferiority Survival Trials Designed for Accrual by Cohorts,” Statistical Methods in Medical Research, 27, 507–520. DOI: https://doi.org/10.1177/0962280216633908.
- Zhou, M., and Kundu, S. (2016), “Some Practical Considerations in Three-Arm Non-Inferiority Trial Design,” Pharmaceutical Statistics, 15, 550–559. DOI: https://doi.org/10.1002/pst.1779.
- Zhu, H. (2017), “Sample Size Calculation for Comparing Two Poisson or Negative Binomial Rates in Noninferiority or Equivalence Trials,” Statistics in Biopharmaceutical Research, 9, 107–115. DOI: https://doi.org/10.1080/19466315.2016.1225594.
- Zhu, H., and Lakkis, H. (2014), “Sample Size Calculation for Comparing Two Negative Binomial Rates,” Statistics in Medicine, 33, 376–387. DOI: https://doi.org/10.1002/sim.5947.